Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2010

01.03.2010 | Gynecologic Oncology

The Role of Pelvic and/or Para-Aortic Lymphadenectomy in Surgical Management of Apparently Early Carcinosarcoma of Uterus

verfasst von: Jeong-Yeol Park, MD, Dae-Yeon Kim, PhD, Jong-Hyeok Kim, PhD, Yong-Man Kim, PhD, Young-Tak Kim, PhD, Joo-Hyun Nam, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Aims

To determine the incidence of lymph node (LN) metastasis in patients with apparently early carcinosarcoma of the uterus, to analyze the clinicopathologic factors associated with LN metastasis, and to evaluate the role of pelvic and/or para-aortic lymphadenectomy in treatment of such conditions.

Methods

We retrospectively analyzed 41 patients with carcinosarcoma intraoperatively confined to the uterus who underwent complete staging procedures including pelvic and/or para-aortic lymphadenectomy.

Results

After surgery, two patients (4.9%) were upstaged to stage IIIA because of positive peritoneal washing cytology, and 13 (31.7%) were upstaged to stage IIIC as a result of LN metastasis. Five patients had pelvic, three had para-aortic, and five had both pelvic and para-aortic LN metastases. The mean number of metastatic LNs was 3.7 (range 1–15). On multivariate analysis, myometrial invasion >1/2 [odds ratio (OR) 8.50; 95% confidence interval (CI) 1.57–45.92; P = 0.013] and lymphovascular space invasion (LVSI) (OR 8.50; 95% CI 1.57–45.92; P = 0.013) were significantly predictive of LN metastasis. After a median follow-up interval of 32 months (range 3–179 months), the 2-year disease-free survival (DFS) and overall survival (OS) rates were 73% and 84%, respectively, and the 5-year DFS and OS rates were 73% and 69%, respectively. Patients with LVSI or LN metastasis had significantly poorer DFS and OS.

Conclusions

Pelvic and para-aortic lymphadenectomy should be performed in patients with apparently early carcinosarcoma of the uterus, especially in those with myometrial invasion >1/2 or LVSI.
Literatur
1.
Zurück zum Zitat Ali S, Wells M. Mixed Mullerian tumors of the uterine corpus: a review. Int J Gynecol Cancer. 1993;3(1):1–11.CrossRefPubMed Ali S, Wells M. Mixed Mullerian tumors of the uterine corpus: a review. Int J Gynecol Cancer. 1993;3(1):1–11.CrossRefPubMed
2.
3.
Zurück zum Zitat Pecorelli S, Benedet JL, Creasman WT, Shepherd JH (1999) FIGO staging of gynecologic cancer. 1994–1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 65(3):243–9CrossRefPubMed Pecorelli S, Benedet JL, Creasman WT, Shepherd JH (1999) FIGO staging of gynecologic cancer. 1994–1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 65(3):243–9CrossRefPubMed
4.
Zurück zum Zitat FIGO. Annual report on the results of treatment in gynecologic cancer. Int J Gynecol Obstet. 2989;28:189–93. FIGO. Annual report on the results of treatment in gynecologic cancer. Int J Gynecol Obstet. 2989;28:189–93.
5.
Zurück zum Zitat Benedet JL, Bender H, Jones H, III, Ngan HY, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 70(2):209–62CrossRefPubMed Benedet JL, Bender H, Jones H, III, Ngan HY, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 70(2):209–62CrossRefPubMed
6.
Zurück zum Zitat Nielsen SN, Podratz KC, Scheithauer BW, O’Brien PC. Clinicopathologic analysis of uterine malignant mixed mullerian tumors. Gynecol Oncol. 1989;34(3):372–8.CrossRefPubMed Nielsen SN, Podratz KC, Scheithauer BW, O’Brien PC. Clinicopathologic analysis of uterine malignant mixed mullerian tumors. Gynecol Oncol. 1989;34(3):372–8.CrossRefPubMed
7.
Zurück zum Zitat Gadducci A, Cosio S, Romanini A, Genazzani AR. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2008;65(2):129–42.CrossRefPubMed Gadducci A, Cosio S, Romanini A, Genazzani AR. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2008;65(2):129–42.CrossRefPubMed
8.
Zurück zum Zitat Gadducci A, Romanini A. Adjuvant chemotherapy in early stage uterine sarcomas: an open question. Eur J Gynaecol Oncol. 2001;22(5):352–7.PubMed Gadducci A, Romanini A. Adjuvant chemotherapy in early stage uterine sarcomas: an open question. Eur J Gynaecol Oncol. 2001;22(5):352–7.PubMed
9.
Zurück zum Zitat Temkin SM, Hellmann M, Lee YC, Abulafia O. Early-stage carcinosarcoma of the uterus: the significance of lymph node count. Int J Gynecol Cancer. 2007;17(1):215–9.CrossRefPubMed Temkin SM, Hellmann M, Lee YC, Abulafia O. Early-stage carcinosarcoma of the uterus: the significance of lymph node count. Int J Gynecol Cancer. 2007;17(1):215–9.CrossRefPubMed
10.
Zurück zum Zitat Major FJ, Blessing JA, Silverberg SG, et al. (1993) Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 71(4):1702–9PubMed Major FJ, Blessing JA, Silverberg SG, et al. (1993) Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 71(4):1702–9PubMed
11.
Zurück zum Zitat McCluggage WG, Haller U, Kurman RJ, et al. Mixed epithelial and mesenchymal tumours. In: Tavassoli FA, Devilee P, editors. World Health Organization classification of tumour. Pahology and genetics of tumours of the breast and female genital organs. Lyon: IARC; 2003. p. 245–49. McCluggage WG, Haller U, Kurman RJ, et al. Mixed epithelial and mesenchymal tumours. In: Tavassoli FA, Devilee P, editors. World Health Organization classification of tumour. Pahology and genetics of tumours of the breast and female genital organs. Lyon: IARC; 2003. p. 245–49.
12.
Zurück zum Zitat Manolitsas TP, Wain GV, Williams KE, Freidlander M, Hacker NF. Multimodality therapy for patients with clinical stage I and II malignant mixed Mullerian tumors of the uterus. Cancer. 2001;91(8):1437–43.CrossRefPubMed Manolitsas TP, Wain GV, Williams KE, Freidlander M, Hacker NF. Multimodality therapy for patients with clinical stage I and II malignant mixed Mullerian tumors of the uterus. Cancer. 2001;91(8):1437–43.CrossRefPubMed
13.
Zurück zum Zitat Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000;88(12):2782–6.CrossRefPubMed Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000;88(12):2782–6.CrossRefPubMed
14.
Zurück zum Zitat Morrow CP. Leiomyosarcoma. In: Morrow CP, Curtin JP, editors. Gynecologic cancer surgery. New York: Churchill Livingstone; 1996. p. 613–16. Morrow CP. Leiomyosarcoma. In: Morrow CP, Curtin JP, editors. Gynecologic cancer surgery. New York: Churchill Livingstone; 1996. p. 613–16.
15.
Zurück zum Zitat Boronow RC, Morrow CP, Creasman WT, Disaia PJ, Silverberg SG, Miller A, Blessing JA. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984;63(6):825–32.PubMed Boronow RC, Morrow CP, Creasman WT, Disaia PJ, Silverberg SG, Miller A, Blessing JA. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984;63(6):825–32.PubMed
16.
Zurück zum Zitat Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB (1987) Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer. 60(8):2035–41PubMed Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB (1987) Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer. 60(8):2035–41PubMed
17.
Zurück zum Zitat Schink JC, Lurain JR, Wallemark CB, Chmiel JS. Tumor size in endometrial cancer: a prognostic factor for lymph node metastasis. Obstet Gynecol. 1987;70(2):216–9.PubMed Schink JC, Lurain JR, Wallemark CB, Chmiel JS. Tumor size in endometrial cancer: a prognostic factor for lymph node metastasis. Obstet Gynecol. 1987;70(2):216–9.PubMed
18.
Zurück zum Zitat Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY, et al. (1990) Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol. 9(1):1–19.CrossRefPubMed Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY, et al. (1990) Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol. 9(1):1–19.CrossRefPubMed
19.
Zurück zum Zitat Podczaski ES, Woomert CA, Stevens CW, Jr, Manetta A, Larson JE, Zaino RJ, et al. Management of malignant, mixed mesodermal tumors of the uterus. Gynecol Oncol. 1989;32(2):240–4.CrossRefPubMed Podczaski ES, Woomert CA, Stevens CW, Jr, Manetta A, Larson JE, Zaino RJ, et al. Management of malignant, mixed mesodermal tumors of the uterus. Gynecol Oncol. 1989;32(2):240–4.CrossRefPubMed
20.
Zurück zum Zitat Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. 2008;111(1):82–8.CrossRefPubMed Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. 2008;111(1):82–8.CrossRefPubMed
21.
Zurück zum Zitat Benedetti Panici P, Basile S, Maneschi F, et al. (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 100(23):1707–16.CrossRefPubMed Benedetti Panici P, Basile S, Maneschi F, et al. (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 100(23):1707–16.CrossRefPubMed
22.
Zurück zum Zitat Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125–36.CrossRefPubMed Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125–36.CrossRefPubMed
Metadaten
Titel
The Role of Pelvic and/or Para-Aortic Lymphadenectomy in Surgical Management of Apparently Early Carcinosarcoma of Uterus
verfasst von
Jeong-Yeol Park, MD
Dae-Yeon Kim, PhD
Jong-Hyeok Kim, PhD
Yong-Man Kim, PhD
Young-Tak Kim, PhD
Joo-Hyun Nam, PhD
Publikationsdatum
01.03.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0833-6

Weitere Artikel der Ausgabe 3/2010

Annals of Surgical Oncology 3/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.